Halicin

Halicin is a JNK1 inhibitor (IC50 = 0.7 µM). It is selective for JNK1 over p38alpha, Furin, and lethal factor (IC50s = >100, >100, and >50 µM, respectively), as well as Akt at 100 µM. Halicin inhibits TNF-alpha-induced phosphorylation of c-Jun in a cell-based assay (EC50 = 6.23 µM). In vivo, halicin (25 mg/kg) reduces blood glucose levels and restores insulin sensitivity in insulin insensitive mice. Halicin is active against carbapenem-resistant Enterobacteriaceae (MICs = 1-10 µg/ml), as well as multidrug-resistant A. baumannii and P. aeruginosa (MICs = 1-10 and 1-100 µg/ml, respectively). It reduces the number of wound tissue colony forming units (CFUs) in a mouse model of A. baumannii wound infection. Halicin (15 mg/kg) also reduces fecal bacterial load in a mouse model of C. difficile infection.Formal Name: 5-[(5-nitro-2-thiazolyl)thio]-1,3,4-thiadiazol-2-amine. CAS Number: 40045-50-9. Synonyms: SU 3327. Molecular Formula: C5H3N5O2S3. Formula Weight: 261.3. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 30 mg/ml, DMSO: 20 mg/ml. lambdamax: 293, 339 nm. SMILES: NC1=NN=C(SC2=NC=C([N+]([O-])=O)S2)S1. InChi Code: InChI=1S/C5H3N5O2S3/c6-3-8-9-5(14-3)15-4-7-1-2(13-4)10(11)12/h1H,(H2,6,8). InChi Key: NQQBNZBOOHHVQP-UHFFFAOYSA-N. Origin: Synthetic.